ActRII Antagonist Increases Red Blood Cell Levels in Sickle-Cell Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for sickle-cell disease, particularly erythropoietin-based treatments, are often ineffective in increasing red blood cell levels and can exacerbate complications such as vaso-occlusive crises, and there is a need for alternative methods to address the disease's associated morbidity and mortality.
Innovation Solution
Administration of an ActRII antagonist, specifically a polypeptide with an amino acid sequence at least 90% identical to SEQ ID NO: 1, which binds to GDF8 and/or GDF11, to inhibit the ActRII signaling pathway, thereby increasing red blood cell levels and reducing the need for transfusions and iron chelation therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If erythropoietin-based treatments are administered to increase red blood cell levels, then red blood cell production is stimulated, but vaso-occlusive crises are exacerbated and treatment effectiveness is reduced
Solution Approach 1:
The patent introduces a novel compound as an intermediary agent that mediates between the need to increase red blood cell production and the need to prevent vaso-occlusive crises. This compound acts through a different mechanism than erythropoietin, stimulating erythropoiesis without triggering the harmful vaso-occlusive responses that limit EPO-based therapies.
Solution Approach 2:
The invention changes the therapeutic parameter from erythropoietin stimulation to a novel compound administration approach. By altering the fundamental mechanism of action and using a different chemical entity, the treatment achieves red blood cell increase while avoiding the exacerbation of vaso-occlusive crises that occurs with traditional EPO-based therapies.
2Productivity
If erythropoietin-based treatments are used to treat sickle-cell disease, then red blood cell formation is promoted, but treatment efficacy is insufficient and complications increase
Solution Approach 1:
A novel compound is introduced as an intermediary therapeutic agent that more reliably achieves the dual goals of increasing red blood cell formation and preventing complications. This intermediary approach overcomes the limitations and unpredictability of erythropoietin-based treatments in sickle-cell disease patients.
Solution Approach 2:
The patent employs a novel compound that copies or mimics the beneficial effects of erythropoietin on red blood cell production while eliminating the harmful side effects. This copying approach allows the treatment to achieve the desired productivity improvement without compromising reliability.
3Object-affected harmful factors
If traditional therapies are administered to manage sickle-cell disease, then some symptoms are addressed, but morbidity and mortality rates remain high
Solution Approach 1:
The novel compound serves as an intermediary therapeutic that addresses the insufficiency of traditional symptom-management approaches. By acting through a different mechanism, it provides more reliable protection against morbidity and mortality while still managing disease symptoms.
Solution Approach 2:
The patent introduces a novel compound that provides a more effective and potentially more accessible treatment option compared to traditional therapies. This approach aims to replace expensive and less effective traditional treatments with a more reliable solution that can significantly reduce morbidity and mortality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ActRII antagonist effectively increases red blood cell parameters, improves red blood cell morphology, and reduces the severity of complications like vaso-occlusion and pain crises, thereby improving quality of life and reducing mortality associated with sickle-cell disease.
Implementation Method 1
a polypeptide with an amino acid sequence at least 90% identical to SEQ ID NO: 1, which binds to GDF8 and/or GDF11
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
In certain aspects, the present disclosure provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans. In some embodiments, the compositions of the disclosure may be used to treat or prevent sickle-cell disease or one or more complications associated with sickle-cell disease.